Open Heart

Prognostic value of baseline and longitudinal changes in exercise capacity and quality of life in the HF-Wii Swedish population

This study aimed to explore whether baseline values and 12-month change in the 6-Minute Walk Distance (6MWD) and the physical ...

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

FDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell ...